Table 1.
Clinical trials of adjuvant immunotherapies for NSCLC
| Study name | Drug | Sample size | Hazard ratio for OS | Hazard ratio for PFS | Identifier |
|---|---|---|---|---|---|
| MAGRIT | GSK1572932A Antigen-Specific Cancer Immunotherapeutic | 2312 | None | 1.02 (95% CI: 0.89–1.18) | NCT00480025 |
| PEARLS | Pembrolizumab | 1080 (Estimated) | Ongoing | Ongoing | NCT02504372 |
| BR31 | Durvalumab | 1360 (Estimated) | Ongoing | Ongoing | NCT02273375 |
| IMpower010 | Atezolizumab | 1280 (Estimated) | Ongoing | Ongoing | NCT02486718 |
| ANVIL | Nivolumab | 903 (Estimated) | Ongoing | Ongoing | NCT02595944 |
Abbreviations: OS, overall survival; PFS, progression-free survival.